Breaking News

Over a week ago
Show Full Stories

X

To view all stories in expanded form, please subscribe.
Send Info
Downgrade
MorphoSys downgraded to Neutral from Buy at Citi » 04:40
09/27/21
09/27
04:40
09/27/21
04:40
MOR

MorphoSys

$12.21 /

-0.265 (-2.12%)

Citi analyst Vineet…

Citi analyst Vineet Agrawal downgraded MorphoSys to Neutral from Buy with a EUR 52 price target. The stock is down 56% year-to-date on the "lackluster" Monjuvi launch but there is few near-term catalysts to change investor sentiment, Agrawal tells investors in a research note.

ShowHide Related Items >><<
MOR MorphoSys
$12.21 /

-0.265 (-2.12%)

MOR MorphoSys
$12.21 /

-0.265 (-2.12%)

09/13/21 Goldman Sachs
MorphoSys reinstated with a Neutral at Goldman Sachs
09/02/21 Barclays
MorphoSys price target lowered to EUR 47 from EUR 90 at Barclays
08/06/21 Deutsche Bank
MorphoSys downgraded to Hold from Buy at Deutsche Bank
08/05/21 Deutsche Bank
MorphoSys downgraded to Hold from Buy at Deutsche Bank
MOR MorphoSys
$12.21 /

-0.265 (-2.12%)

MOR MorphoSys
$12.21 /

-0.265 (-2.12%)

Over a month ago
Conference/Events
MorphoSys participates in a conference call with JPMorgan » 10:02
09/23/21
09/23
10:02
09/23/21
10:02
MOR

MorphoSys

$12.38 /

+0.23 (+1.89%)

European Pharma &…

European Pharma & Biotech Analyst holds a conference call with CEO Kress on September 23 at 11 am hosted by JPMorgan.

ShowHide Related Items >><<
MOR MorphoSys
$12.38 /

+0.23 (+1.89%)

MOR MorphoSys
$12.38 /

+0.23 (+1.89%)

09/13/21 Goldman Sachs
MorphoSys reinstated with a Neutral at Goldman Sachs
09/02/21 Barclays
MorphoSys price target lowered to EUR 47 from EUR 90 at Barclays
08/06/21 Deutsche Bank
MorphoSys downgraded to Hold from Buy at Deutsche Bank
08/05/21 Deutsche Bank
MorphoSys downgraded to Hold from Buy at Deutsche Bank
MOR MorphoSys
$12.38 /

+0.23 (+1.89%)

MOR MorphoSys
$12.38 /

+0.23 (+1.89%)

Initiation
MorphoSys reinstated with a Neutral at Goldman Sachs » 04:45
09/13/21
09/13
04:45
09/13/21
04:45
MOR

MorphoSys

$12.93 /

-0.68 (-5.00%)

Goldman Sachs analyst…

Goldman Sachs analyst Graig Suvannavejh reinstated coverage of MorphoSys with a Neutral rating and $12 price target following the closing of the acquisition of Constellation Pharma. The deal adds meaningful operating expenditures, which pushes out the company's first-year profitability, Suvannavejh tells investors in a research note. The analyst awaits an inflection in sales of Monjuvi, and with meaningful late-stage clinical data read outs not expected until 2024-2025, he sees MorphoSys as a "show me" story.

ShowHide Related Items >><<
MOR MorphoSys
$12.93 /

-0.68 (-5.00%)

MOR MorphoSys
$12.93 /

-0.68 (-5.00%)

09/02/21 Barclays
MorphoSys price target lowered to EUR 47 from EUR 90 at Barclays
08/06/21 Deutsche Bank
MorphoSys downgraded to Hold from Buy at Deutsche Bank
08/05/21 Deutsche Bank
MorphoSys downgraded to Hold from Buy at Deutsche Bank
08/04/21 Morgan Stanley
MorphoSys price target lowered to EUR 75 from EUR 86 at Morgan Stanley
MOR MorphoSys
$12.93 /

-0.68 (-5.00%)

MOR MorphoSys
$12.93 /

-0.68 (-5.00%)

Recommendations
MorphoSys price target lowered to EUR 47 from EUR 90 at Barclays » 13:52
09/02/21
09/02
13:52
09/02/21
13:52
MOR

MorphoSys

$15.03 /

+0.03 (+0.20%)

Barclays analyst Emmanuel…

Barclays analyst Emmanuel Papadakis lowered the firm's price target on MorphoSys to EUR 47 from EUR 90 and keeps an Equal Weight rating on the shares.

ShowHide Related Items >><<
MOR MorphoSys
$15.03 /

+0.03 (+0.20%)

MOR MorphoSys
$15.03 /

+0.03 (+0.20%)

08/06/21 Deutsche Bank
MorphoSys downgraded to Hold from Buy at Deutsche Bank
08/05/21 Deutsche Bank
MorphoSys downgraded to Hold from Buy at Deutsche Bank
08/04/21 Morgan Stanley
MorphoSys price target lowered to EUR 75 from EUR 86 at Morgan Stanley
08/04/21 JPMorgan
MorphoSys price target lowered to EUR 54 from EUR 80 at JPMorgan
MOR MorphoSys
$15.03 /

+0.03 (+0.20%)

MOR MorphoSys
$15.03 /

+0.03 (+0.20%)

On The Fly
Fly Intel: After-Hours Movers » 18:27
08/26/21
08/26
18:27
08/26/21
18:27
BILL

Bill.com

$219.20 /

-0.235 (-0.11%)

, GPS

Gap

$26.36 /

-1.11 (-4.04%)

, LTRX

Lantronix

$5.24 /

+0.06 (+1.16%)

, WDAY

Workday

$246.78 /

+0.66 (+0.27%)

, MOR

MorphoSys

$14.14 /

-0.1 (-0.70%)

, OLLI

Ollie's Bargain Outlet

$77.81 /

-5.39 (-6.48%)

, DOMO

Domo

$97.73 /

+0.96 (+0.99%)

, PTON

Peloton

$114.13 /

-2.05 (-1.76%)

, VMW

VMware

$158.71 /

+0.26 (+0.16%)

, MRVL

Marvell

$63.23 /

+0.03 (+0.05%)

, DELL

Dell Technologies

$101.54 /

-0.53 (-0.52%)

, HPQ

HP Inc.

$29.12 /

-0.28 (-0.95%)

Check out this evening's…

ShowHide Related Items >><<
WDAY Workday
$246.78 /

+0.66 (+0.27%)

VMW VMware
$158.71 /

+0.26 (+0.16%)

PTON Peloton
$114.13 /

-2.05 (-1.76%)

OLLI Ollie's Bargain Outlet
$77.81 /

-5.39 (-6.48%)

MRVL Marvell
$63.23 /

+0.03 (+0.05%)

MOR MorphoSys
$14.14 /

-0.1 (-0.70%)

LTRX Lantronix
$5.24 /

+0.06 (+1.16%)

HPQ HP Inc.
$29.12 /

-0.28 (-0.95%)

GPS Gap
$26.36 /

-1.11 (-4.04%)

DOMO Domo
$97.73 /

+0.96 (+0.99%)

DELL Dell Technologies
$101.54 /

-0.53 (-0.52%)

BILL Bill.com
$219.20 /

-0.235 (-0.11%)

BILL Bill.com
$219.20 /

-0.235 (-0.11%)

08/25/21 BTIG
Bill.com price target raised to $240 from $220 at BTIG
08/19/21
Fly Intel: Top five analyst upgrades
08/19/21 Jefferies
Bill.com upgraded to Buy from Hold at Jefferies
07/14/21 Canaccord
Bill.com assumed with a Buy at Canaccord
GPS Gap
$26.36 /

-1.11 (-4.04%)

08/03/21 Wells Fargo
Athleta 'highly undervalued' withing Gap, says Wells Fargo
07/26/21 Deutsche Bank
Gap upgraded to Buy from Hold at Deutsche Bank
07/14/21 Goldman Sachs
Gap initiated with a Neutral at Goldman Sachs
07/06/21
Fly Intel: Top five analyst initiations
LTRX Lantronix
$5.24 /

+0.06 (+1.16%)

07/08/21 Needham
Lantronix initiated with a Buy at Needham
07/08/21 Needham
Lantronix initiated with a Buy at Needham
WDAY Workday
$246.78 /

+0.66 (+0.27%)

08/19/21 Oppenheimer
Workday assumed with an Outperform at Oppenheimer
08/03/21
Fly Intel: Top five analyst upgrades
08/03/21 Barclays
Workday upgraded to Overweight from Equal Weight at Barclays
07/27/21 KeyBanc
Workday HCM rollout termination at Amazon not a competitive loss, says KeyBanc
MOR MorphoSys
$14.14 /

-0.1 (-0.70%)

08/06/21 Deutsche Bank
MorphoSys downgraded to Hold from Buy at Deutsche Bank
08/05/21 Deutsche Bank
MorphoSys downgraded to Hold from Buy at Deutsche Bank
08/04/21 Morgan Stanley
MorphoSys price target lowered to EUR 75 from EUR 86 at Morgan Stanley
08/04/21 JPMorgan
MorphoSys price target lowered to EUR 54 from EUR 80 at JPMorgan
OLLI Ollie's Bargain Outlet
$77.81 /

-5.39 (-6.48%)

05/28/21 Piper Sandler
Ollie's Bargain Outlet price target raised to $112 from $107 at Piper Sandler
05/24/21
Fly Intel: Top five analyst upgrades
05/24/21 Morgan Stanley
Ollie's upgraded to Equal Weight from Underweight at Morgan Stanley
05/17/21 JPMorgan
Ollie's Bargain Outlet price target lowered to $95 from $109 at JPMorgan
DOMO Domo
$97.73 /

+0.96 (+0.99%)

06/23/21 Cowen
Domo price target raised to $100 from $89 at Cowen
05/28/21 Needham
Domo price target raised to $93 from $91 at Needham
03/15/21 Credit Suisse
Domo assumed with a Neutral at Credit Suisse
03/15/21
Fly Intel: Top five analyst upgrades
PTON Peloton
$114.13 /

-2.05 (-1.76%)

08/26/21 Needham
Peloton price target raised to $135 from $125 at Needham
08/24/21 Truist
Peloton announces August 30 launch data for Tread, says Truist
08/24/21 Truist
Peloton price target lowered to $130 from $140 at Truist
08/24/21 JPMorgan
JPMorgan lowers Peloton subscriber estimates but remains bullish
VMW VMware
$158.71 /

+0.26 (+0.16%)

08/13/21 Tigress Financial
VMware shares going to $206 in 12 months, says Tigress Financial
06/25/21
Fly Intel: Top five analyst initiations
06/25/21 Raymond James
VMware resumed with an Outperform at Raymond James
06/25/21 Raymond James
VMware resumed with an Outperform at Raymond James
MRVL Marvell
$63.23 /

+0.03 (+0.05%)

08/25/21 Susquehanna
Marvell price target raised to $72 from $64 at Susquehanna
08/24/21 Stifel
Stifel ups Marvell target to $70 ahead of results
08/23/21 B. Riley
Marvell price target raised to $72 from $66 at B. Riley
08/23/21 BMO Capital
Marvell price target raised to $70 from $60 at BMO Capital
DELL Dell Technologies
$101.54 /

-0.53 (-0.52%)

08/20/21 Evercore ISI
Dell Technologies added to Tactical Outperform List at Evercore ISI
08/05/21 OTR Global
Dell Technologies view upgraded to Positive from Mixed at OTR Global
06/10/21 Morgan Stanley
Seagate, Dell, NCR, NetApp top picks in IT Hardware at Morgan Stanley
05/28/21 Morgan Stanley
Dell Technologies price target raised to $130 from $127 at Morgan Stanley
HPQ HP Inc.
$29.12 /

-0.28 (-0.95%)

08/09/21
Fly Intel: Top five analyst initiations
08/09/21 Jefferies
HP Inc. initiated with a Hold at Jefferies
08/09/21 Jefferies
HP Inc. initiated with a Hold at Jefferies
07/02/21 Bernstein
HP plus Xerox 'consolidation math compelling,' says Bernstein
WDAY Workday
$246.78 /

+0.66 (+0.27%)

VMW VMware
$158.71 /

+0.26 (+0.16%)

PTON Peloton
$114.13 /

-2.05 (-1.76%)

OLLI Ollie's Bargain Outlet
$77.81 /

-5.39 (-6.48%)

MRVL Marvell
$63.23 /

+0.03 (+0.05%)

MOR MorphoSys
$14.14 /

-0.1 (-0.70%)

LTRX Lantronix
$5.24 /

+0.06 (+1.16%)

HPQ HP Inc.
$29.12 /

-0.28 (-0.95%)

GPS Gap
$26.36 /

-1.11 (-4.04%)

DOMO Domo
$97.73 /

+0.96 (+0.99%)

DELL Dell Technologies
$101.54 /

-0.53 (-0.52%)

BILL Bill.com
$219.20 /

-0.235 (-0.11%)

  • 02
    Sep
WDAY Workday
$246.78 /

+0.66 (+0.27%)

PTON Peloton
$114.13 /

-2.05 (-1.76%)

MRVL Marvell
$63.23 /

+0.03 (+0.05%)

HPQ HP Inc.
$29.12 /

-0.28 (-0.95%)

GPS Gap
$26.36 /

-1.11 (-4.04%)

DELL Dell Technologies
$101.54 /

-0.53 (-0.52%)

BILL Bill.com
$219.20 /

-0.235 (-0.11%)

WDAY Workday
$246.78 /

+0.66 (+0.27%)

VMW VMware
$158.71 /

+0.26 (+0.16%)

PTON Peloton
$114.13 /

-2.05 (-1.76%)

OLLI Ollie's Bargain Outlet
$77.81 /

-5.39 (-6.48%)

MRVL Marvell
$63.23 /

+0.03 (+0.05%)

MOR MorphoSys
$14.14 /

-0.1 (-0.70%)

HPQ HP Inc.
$29.12 /

-0.28 (-0.95%)

GPS Gap
$26.36 /

-1.11 (-4.04%)

DOMO Domo
$97.73 /

+0.96 (+0.99%)

DELL Dell Technologies
$101.54 /

-0.53 (-0.52%)

BILL Bill.com
$219.20 /

-0.235 (-0.11%)

WDAY Workday
$246.78 /

+0.66 (+0.27%)

VMW VMware
$158.71 /

+0.26 (+0.16%)

PTON Peloton
$114.13 /

-2.05 (-1.76%)

MRVL Marvell
$63.23 /

+0.03 (+0.05%)

LTRX Lantronix
$5.24 /

+0.06 (+1.16%)

HPQ HP Inc.
$29.12 /

-0.28 (-0.95%)

GPS Gap
$26.36 /

-1.11 (-4.04%)

DELL Dell Technologies
$101.54 /

-0.53 (-0.52%)

Hot Stocks
MorphoSys spikes 6% after EC grants conditional MA for Minjuvi combo treatment » 17:25
08/26/21
08/26
17:25
08/26/21
17:25
MOR

MorphoSys

$14.14 /

-0.1 (-0.70%)

, INCY

Incyte

$75.12 /

-0.6 (-0.79%)

Shares of MorphoSys (MOR)…

Shares of MorphoSys (MOR) are up approximately 6% or 87c per share to $15.00 per share in after hours trading after Incyte (INCY) and MorphoSy announced that the European Commission or EC, has granted conditional marketing authorization for Minjuvi or tafasitamab, in combination with lenalidomide for certain DLBCL treatment.

ShowHide Related Items >><<
MOR MorphoSys
$14.14 /

-0.1 (-0.70%)

INCY Incyte
$75.12 /

-0.6 (-0.79%)

MOR MorphoSys
$14.14 /

-0.1 (-0.70%)

08/06/21 Deutsche Bank
MorphoSys downgraded to Hold from Buy at Deutsche Bank
08/05/21 Deutsche Bank
MorphoSys downgraded to Hold from Buy at Deutsche Bank
08/04/21 Morgan Stanley
MorphoSys price target lowered to EUR 75 from EUR 86 at Morgan Stanley
08/04/21 JPMorgan
MorphoSys price target lowered to EUR 54 from EUR 80 at JPMorgan
INCY Incyte
$75.12 /

-0.6 (-0.79%)

07/20/21 Benchmark
Incyte upgraded to Buy from Hold at Benchmark
06/25/21 RBC Capital
Incyte price target lowered to $88 from $92 at RBC Capital
06/23/21 Benchmark
Incyte's retifanlimab does not seem likely to be approved, says Benchmark
02/10/21 SVB Leerink
Incyte downgraded to Market Perform from Outperform at SVB Leerink
MOR MorphoSys
$14.14 /

-0.1 (-0.70%)

INCY Incyte
$75.12 /

-0.6 (-0.79%)

INCY Incyte
$75.12 /

-0.6 (-0.79%)

MOR MorphoSys
$14.14 /

-0.1 (-0.70%)

INCY Incyte
$75.12 /

-0.6 (-0.79%)

Hot Stocks
MorphoSys, Incyte get EC conditional MA for Minjuvi-lenalidomide combo for DLBCL » 16:15
08/26/21
08/26
16:15
08/26/21
16:15
MOR

MorphoSys

$14.14 /

-0.1 (-0.70%)

, INCY

Incyte

$75.12 /

-0.6 (-0.79%)

MorphoSys (MOR) and…

MorphoSys (MOR) and Incyte (INCY) announced that the European Commission has granted conditional marketing authorization for Minjuvi, tafasitamab, in combination with lenalidomide, followed by Minjuvi monotherapy, for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma who are not eligible for autologous stem cell transplant . The EC Decision follows the positive opinion received from the European Medicines Agency's Committee for Medicinal Products for Human Use in June 2021 recommending the conditional marketing authorization of Minjuvi. "People living with relapsed or refractory DLBCL in the EU have historically had limited treatment options and a poor prognosis. However, with the EC's approval of Minjuvi, eligible patients now have a new and much needed treatment option," said Herve Hoppenot, Chief Executive Officer, Incyte. "We will now focus our efforts on working with individual countries in Europe to provide people access to this new treatment." "The approval of Minjuvi is a crucial milestone for patients with relapsed or refractory DLBCL in Europe, "said Jean-Paul Kress, M.D., Chief Executive Officer, MorphoSys. "DLBCL is the most common type of non-Hodgkin lymphoma in adults and Minjuvi addresses an urgent unmet medical need for the 30-40% of people who do not respond to or relapse after initial therapy." The conditional approval is based on the results from the L-MIND study evaluating the safety and efficacy of tafasitamab in combination with lenalidomide as a treatment for patients with relapsed or refractory DLBCL who are not eligible for autologous stem cell transplant . The results showed best objective response rate of 56.8%, primary endpoint, including a complete response rate of 39.5% and a partial response rate of 17.3%, as assessed by an independent review committee. The median duration of response was 43.9 months after a minimum follow up of 35 months, secondary endpoint. Tafasitamab together with lenalidomide was shown to provide a clinically meaningful response and the side effects were manageable. Warnings and precautions for tafasitamab include infusion-related reactions, myelosuppression, including neutropenia and thrombocytopenia, infections and tumour lysis syndrome.

ShowHide Related Items >><<
MOR MorphoSys
$14.14 /

-0.1 (-0.70%)

INCY Incyte
$75.12 /

-0.6 (-0.79%)

MOR MorphoSys
$14.14 /

-0.1 (-0.70%)

08/06/21 Deutsche Bank
MorphoSys downgraded to Hold from Buy at Deutsche Bank
08/05/21 Deutsche Bank
MorphoSys downgraded to Hold from Buy at Deutsche Bank
08/04/21 Morgan Stanley
MorphoSys price target lowered to EUR 75 from EUR 86 at Morgan Stanley
08/04/21 JPMorgan
MorphoSys price target lowered to EUR 54 from EUR 80 at JPMorgan
INCY Incyte
$75.12 /

-0.6 (-0.79%)

07/20/21 Benchmark
Incyte upgraded to Buy from Hold at Benchmark
06/25/21 RBC Capital
Incyte price target lowered to $88 from $92 at RBC Capital
06/23/21 Benchmark
Incyte's retifanlimab does not seem likely to be approved, says Benchmark
02/10/21 SVB Leerink
Incyte downgraded to Market Perform from Outperform at SVB Leerink
MOR MorphoSys
$14.14 /

-0.1 (-0.70%)

INCY Incyte
$75.12 /

-0.6 (-0.79%)

INCY Incyte
$75.12 /

-0.6 (-0.79%)

MOR MorphoSys
$14.14 /

-0.1 (-0.70%)

INCY Incyte
$75.12 /

-0.6 (-0.79%)

Downgrade
MorphoSys downgraded to Hold from Buy at Deutsche Bank » 04:51
08/06/21
08/06
04:51
08/06/21
04:51
MOR

MorphoSys

$13.74 /

+0.3 (+2.23%)

Deutsche Bank analyst…

Deutsche Bank analyst Rajan Sharma downgraded MorphoSys to Hold from Buy with a price target of EUR 46, down from EUR 116. The Q2 results brought a "clear negative signal" from management on short to medium-term Monjuvi expectations, Sharma tells investors in a research note. The guidance cut, balance sheet liability reduction attributable to Monjuvi profits and subsequent call commentary suggest that the drivers of Monjuvi's disappointing launch go beyond the challenges posed by the pandemic and "call into question the company's commercialization strategy," says the analyst. As such, Sharma sees a lack of catalysts for MorphoSys shares.

ShowHide Related Items >><<
MOR MorphoSys
$13.74 /

+0.3 (+2.23%)

MOR MorphoSys
$13.74 /

+0.3 (+2.23%)

08/05/21 Deutsche Bank
MorphoSys downgraded to Hold from Buy at Deutsche Bank
08/04/21 Morgan Stanley
MorphoSys price target lowered to EUR 75 from EUR 86 at Morgan Stanley
08/04/21 JPMorgan
MorphoSys price target lowered to EUR 54 from EUR 80 at JPMorgan
07/27/21 SVB Leerink
MorphoSys price target lowered to EUR 96 from EUR 106 at SVB Leerink
MOR MorphoSys
$13.74 /

+0.3 (+2.23%)

MOR MorphoSys
$13.74 /

+0.3 (+2.23%)

Downgrade
MorphoSys downgraded to Hold from Buy at Deutsche Bank » 15:29
08/05/21
08/05
15:29
08/05/21
15:29
MOR

MorphoSys

$13.82 /

+0.38 (+2.83%)

Deutsche Bank analyst…

Deutsche Bank analyst Rajan Sharma downgraded MorphoSys to Hold from Buy.

ShowHide Related Items >><<
MOR MorphoSys
$13.82 /

+0.38 (+2.83%)

MOR MorphoSys
$13.82 /

+0.38 (+2.83%)

08/04/21 Morgan Stanley
MorphoSys price target lowered to EUR 75 from EUR 86 at Morgan Stanley
08/04/21 JPMorgan
MorphoSys price target lowered to EUR 54 from EUR 80 at JPMorgan
07/27/21 SVB Leerink
MorphoSys price target lowered to EUR 96 from EUR 106 at SVB Leerink
07/27/21 Commerzbank
MorphoSys downgraded to Hold from Buy at Commerzbank
MOR MorphoSys
$13.82 /

+0.38 (+2.83%)

MOR MorphoSys
$13.82 /

+0.38 (+2.83%)

Recommendations
MorphoSys price target lowered to EUR 75 from EUR 86 at Morgan Stanley » 14:12
08/04/21
08/04
14:12
08/04/21
14:12
MOR

MorphoSys

$13.39 /

-0.32 (-2.33%)

Morgan Stanley analyst…

Morgan Stanley analyst James Quigley lowered the firm's price target on MorphoSys to EUR 75 from EUR 86 and keeps an Overweight rating on the shares.

ShowHide Related Items >><<
MOR MorphoSys
$13.39 /

-0.32 (-2.33%)

MOR MorphoSys
$13.39 /

-0.32 (-2.33%)

08/04/21 JPMorgan
MorphoSys price target lowered to EUR 54 from EUR 80 at JPMorgan
07/27/21 SVB Leerink
MorphoSys price target lowered to EUR 96 from EUR 106 at SVB Leerink
07/27/21 Commerzbank
MorphoSys downgraded to Hold from Buy at Commerzbank
07/09/21 Morgan Stanley
MorphoSys price target lowered to EUR 86 from EUR 90 at Morgan Stanley
MOR MorphoSys
$13.39 /

-0.32 (-2.33%)

MOR MorphoSys
$13.39 /

-0.32 (-2.33%)

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.